Last reviewed · How we verify
NCT06331923
Assessing the Effectiveness of Continuous Glucose Monitoring in Enhancing Surgical Outcomes for Patients with Diabetes
NA trial testing Continuous glucose monitoring (CGM) device in Comprehensive Complication Index in 10,168 participants. Currently enrolling.
31 October 2025
Quick facts
| Lead sponsor | Beijing Tsinghua Chang Gung Hospital |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 10,168 |
| Start date | 12 April 2024 |
| Primary completion | 31 October 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Continuous glucose monitoring (CGM) device
Conditions studied
- Comprehensive Complication Index — all drugs for Comprehensive Complication Index →
Sponsor
Beijing Tsinghua Chang Gung Hospital
Who can join
18 and older, any sex, with Comprehensive Complication Index. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this multi-center, pragmatic, randomized controlled trial is to assess the effectiveness of continuous glucose monitoring (CGM) compared with conventional monitoring in enhancing surgical outcomes for diabetic patients. The main questions it aims to answer are: * To assess the effectiveness of CGM compared with conventional monitoring in reducing the comprehensive complication index (CCI) for patients with diabetes or impaired glucose tolerance (IGT) within 30 days after surgery. * To analyze the impact of different age groups, types of surgery, preoperative levels of HbA1c, and preoperative 24h glycemic variations on the improvement of surgical outcomes under the CGM model. Participants will receive CGM prescribed by the attending physician for at least 6 hours before surgery. Glucose monitoring should be continued until the 7th day after surgery or discharge. The investigators will compare conventional monitoring group to see if CGM could reduce the CCIs for patients with diabetes or impaired glucose tolerance within 30 days after surgery.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Assessing the effectiveness of continuous glucose monitoring compared with conventional monitoring in enhancing surgical outcomes for patients with diabetes: protocol for a multicentre, parallel-arm, randomised, pragmatic trial in China.
Duan Y, Ding L, Gao Z, Wang Y, et al · · 2025 · cited 1× · PMID 39965943 · DOI 10.1136/bmjopen-2024-090664
Verify or expand the search:
- PubMed search for NCT06331923
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Continuous glucose monitoring (CGM) device
Trials testing the same drug.
- NCT06645873 — Exploration of Continuous Glucose Monitoring on the Intensive Care Unit · NA · completed
Other Beijing Tsinghua Chang Gung Hospital trials
Trials by the same sponsor.
- NCT07123675 — AI-Assisted Blood Pressure Control During Anesthesia · NA · not yet recruiting
- NCT07152496 — Host-Microbe Interactions in Biliary Dilatation · not yet recruiting
- NCT07330271 — PTC-Guided Therapy for Peritoneal Mesothelioma · NA · recruiting
- NCT07328737 — One vs Three HIPEC Cycles After CRS for Pseudomyxoma Peritonei · NA · recruiting
- NCT07044947 — Oteseconazole in the Treatment of Adults With Vulvovaginal Candidiasis（VVC） · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06331923 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing Tsinghua Chang Gung Hospital
- Last refreshed: 27 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06331923.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing